• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Amgen looking for a merger with AZ

anonymous

Guest
  • Amgen to acquire the oncology portfolio of AZ
  • Amgen inherits the Repsiratory franchise including TSLP antibody for sever asthma
  • Amgen gets near term Anemia drug from AZ partnered with Fibrogen
  • Amgen also gets legacy CV drugs
  • This portfolio will allow for stronger contracting multiple products in a therapeutic area

Amgen is waiting for AZ to fail to deliver their revenue promise and then buy them out on the downswing when their management is shaky. They are hoping for a Celgene like drop in valuation.
 

<



  • Amgen to acquire the oncology portfolio of AZ
  • Amgen inherits the Repsiratory franchise including TSLP antibody for sever asthma
  • Amgen gets near term Anemia drug from AZ partnered with Fibrogen
  • Amgen also gets legacy CV drugs
  • This portfolio will allow for stronger contracting multiple products in a therapeutic area
Amgen is waiting for AZ to fail to deliver their revenue promise and then buy them out on the downswing when their management is shaky. They are hoping for a Celgene like drop in valuation.

Amgen has got to do something, they have sitting on their ass doing nothing since bringing all that cash back from overseas and product sales are dropping. Or someone will swoop in and take them over which is never a good deal for the acquired.
 












  • Amgen to acquire the oncology portfolio of AZ
  • Amgen inherits the Repsiratory franchise including TSLP antibody for sever asthma
  • Amgen gets near term Anemia drug from AZ partnered with Fibrogen
  • Amgen also gets legacy CV drugs
  • This portfolio will allow for stronger contracting multiple products in a therapeutic area
Amgen is waiting for AZ to fail to deliver their revenue promise and then buy them out on the downswing when their management is shaky. They are hoping for a Celgene like drop in valuation.
AZN up on Q4 results so forget it!
 




It’s tough to buy AstraZeneca.

They would want the headquarters of the merged company to be in London, or Cambridge in the UK. They would be asking for a 70% premium over their present stock price. And they would want guarantees that few if any UK or Swedish employees be considered for layoff after the merger.

Even if Amgen were to agree to all this, it is highly unlikely the UK and Swedish governments and their public will agree to a foreign takeover of one of its national, industrial champions.
 




  • Amgen to acquire the oncology portfolio of AZ
  • Amgen inherits the Repsiratory franchise including TSLP antibody for sever asthma
  • Amgen gets near term Anemia drug from AZ partnered with Fibrogen
  • Amgen also gets legacy CV drugs
  • This portfolio will allow for stronger contracting multiple products in a therapeutic area
Amgen is waiting for AZ to fail to deliver their revenue promise and then buy them out on the downswing when their management is shaky. They are hoping for a Celgene like drop in valuation.
I'll bet that you have a punchable face!
 




  • Amgen to acquire the oncology portfolio of AZ
  • Amgen inherits the Repsiratory franchise including TSLP antibody for sever asthma
  • Amgen gets near term Anemia drug from AZ partnered with Fibrogen
  • Amgen also gets legacy CV drugs
  • This portfolio will allow for stronger contracting multiple products in a therapeutic area
Amgen is waiting for AZ to fail to deliver their revenue promise and then buy them out on the downswing when their management is shaky. They are hoping for a Celgene like drop in valuation.
As an employee at Celgene it’s embarrassing what is about to happen. Incompetent executive management killed the company.